2024 A Focus on Lung Cancers

Tuesday, june 25, 2024 | 1-5 p.m. ET 
live via zoom webinar

Register Now

Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of clinical implementation of immunotherapy for lung cancer. FREE for healthcare professionals, students, patients and patient advocates.

New for 2024

  • Presentations and discussions intended to promote audience engagement
  • Begins with a debate on continuing immunotherapy after a complete pathologic response, and polling questions will be used throughout the duration of the program
  • Cancer Immunotherapy in Practice will feature a discussion on immunotherapy and biomarker-driven lung cancer
The 2024 Advances in Cancer Immunotherapy™ series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc.  (MSD), and Novartis Pharmaceuticals Corporation (supporters as of March 22, 2024).

Program Organizers

Narjust Florez, MD
Dana-Farber Cancer Institute

Kai He, MD, PhD
The Ohio State University

Ticiana A. Leal, MD
Emory University 

Program Snapshot

Credits Available
Physician Education: 3.75 AMA PRA Category 1TM
Pharmacy Education: 3.75 contact hours (0.375 CEUs)
Nursing Education: 3.75 contact hours

Program Date & Location

Tuesday, June 25, 2024 at 1-5 p.m. ET
Live via Zoom Webinar

Program Cost

FREE for healthcare professionals, students, patients and patient advocates.

Register for A Focus on Lung Cancers >

Program Agenda

1:00–1:05 p.m.

 

Welcome and Introduction

1:05–1:30 p.m.

 

Debate: Continuing Immunotherapy After Complete Pathologic Response

Deb Doroshow, MD, PhD - Icahn School of Medicine at Mount Sinai

Patrick Forde, MD - Johns Hopkins University School of Medicine

1:30–1:55 p.m.

  

Rechallenge with Immunotherapy After Adverse Events

Elad Sharon, MD - Dana-Farber Cancer Institute

1:55–2:20 p.m.

 

Defining Resistance After Front-Line Immunotherapy for NSCLC

Ticiana Leal, MD – Emory University

2:20–2:45 p.m.

 

Updates on Immunotherapy in the Front-Line Setting

Narjust Florez, MD - Dana-Farber Cancer Institute

2:45–3:10 p.m.

 

Emerging Immunotherapy Strategies for Small Cell Lung Cancer

Nagla Karim, MD - Inova Schar Cancer Institute

3:10–3:25 p.m.

 

Break

3:25–4:05 p.m.

 

Cancer Immunotherapy in Practice
Do's and Don'ts for Immunotherapy of Biomarker-Driven Lung Cancer

Kai He, MD, PhD - Ohio State University James Cancer Hospital 

4:05–5 p.m.

 

Faculty Panel

5 p.m.

 

Closing Remarks

SITC ACI Series

This program is part of the SITC ACI series. View below to explore more programs in the 2024 ACI series.


Program Details

Target Audience

The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Case Study Submission Information

As part of the program, registrants are encouraged to submit case studies for expert review during the case study panel concluding the program. If you are interested in taking advantage of this opportunity, please review and sign the linked case study guidelines, and return your case study and signed guidelines to education@sitcancer.org.

Program Learning Objectives

  • Summarize recent updates in cancer immunotherapy for lung cancer and toxicity management for key disease states.
  • Implement cancer immunotherapy for lung cancer into clinical practice appropriately.
  • Describe management approaches for difficult or refractory immune-related adverse events.
  • Describe the use of biomarkers to select appropriate cancer immunotherapies for lung cancer patients.

Accreditation Information

Joint Accreditation Statement

thumbnail image In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and the Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)

ABIM_Logo.jpgSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Physician Continuing Medical Education

PACE designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

PACE designates this continuing education activity for 3.75 contact hour(s) (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

Continuing Nursing Education

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 3.75 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

Disclosures and ADA Info

Disclosure of Conflicts of Interest

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

Avoid Fraudulent ACI Websites

Recently, the SITC office received communication about a fraudulent registration website for one of our ACI programs. To help ensure others don’t mistakenly register on an unauthorized, third-party website, we're proactively informing you to ensure you’re able to safely register for the event through the official SITC website, and so that you can confirm the communication you receive is truly from SITC.

All official forthcoming ACI registration information will come from an email address ending in @sitcancer.org. If you have any questions, please contact the SITC office at events@sitcancer.org or 414-271-2456.